Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00470327 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv21
  2. Primary and study completion dates: Dec 2025 to Dec 2030 Collaborators: 1 to 2v20 Show 1 more changeShow less
    • Collaborators: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

  3. 2 versions Re-verified since Nov 29, 2023, no change to tracked fieldsv18-v19
  4. Primary completion date: Dec 2020 to Dec 2025v17
  5. Re-verified, no change to tracked fieldsv16
Show 14 earlier versionsHide 14 earlier versions
  1. Site contact updatedv15
  2. 2 versions Re-verified since Mar 2, 2017, no change to tracked fieldsv13-v14
  3. Eligibility criteria expanded, about 8 wordsv12 See this version in full on ClinicalTrials.gov ↗
  4. Re-verified, no change to tracked fieldsv11
  5. Primary completion date: Dec 2011 to Dec 2020 Completion date: Dec 2013 to Dec 2025v10 Show 1 more changeShow less
    • Completion date: Dec 2013 to Dec 2025
  6. Re-verified, no change to tracked fieldsv9
  7. Collaborator revisedv8 See this version in full on ClinicalTrials.gov ↗
  8. 2 versions Re-verified since Apr 20, 2009, no change to tracked fieldsv6-v7
  9. Collaborator revisedv5 See this version in full on ClinicalTrials.gov ↗
  10. Re-verified, no change to tracked fieldsv4
  11. Completion date: Dec 2010 to Dec 2013v3
  12. Primary completion date: Dec 2011 Completion date: Dec 2010 · Start date: Sep 2005v2 Show 2 more changesShow less
    • Completion date: Dec 2010
    • Start date: Sep 2005
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of these diseases.
Trial Details
NCT Number NCT00470327
Lead Sponsor University of Chicago
Collaborators: Idiopathic Pulmonary Fibrosis Clinical Research Network, National Institute of Allergy and Infectious Diseases (NIAID)
Conditions Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Disorder
Enrollment 4,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov